| Name | Title | Contact Details |
|---|
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.
Dedicated to researching and developing next generation medicine.
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.
McKesson Corporation, currently ranked 7th on the FORTUNE 500, we are a global healthcare services and medical supply company dedicated to delivering better care. We support the entire healthcare system, including pharmacies, hospitals, health systems, biotech and life sciences companies, specialty care and oncology practices, physician offices, surgery centers, and long-term care and home health facilities. We deliver pharmaceutical products, medical supplies and business services to each of these groups to create a world of better health.